Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of NNC0268-0965 in Type 2 Diabetes
NCT04136067Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nnc0268-0965 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Started Oct 2019; status: completed.
02
Drugs
nnc0268-0965
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04136067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136067.